Gene therapy shows long-term benefit for patients with Cerebral adrenoleukodystrophy (CALD)

Gene therapy shows long-term benefit for patients with Cerebral adrenoleukodystrophy (CALD)

Overview:

In a study published in The New England Journal of Medicine, lentiviral gene therapy using elivaldogene autotemcel (eli-cel) showed promising results in treating cerebral adrenoleukodystrophy (CALD) in boys. Over a 24-month period, 91% of participants survived without major functional disabilities, and 94% showed stable neurologic function over a median of 6 years. While the therapy was largely effective, one patient developed myelodysplastic syndrome, highlighting an ongoing risk associated with viral vector therapies. For more details, you can access the full study here.

*The United Leukodystrophy Foundation is not liable for any inaccuracies or gaps in these overviews , which are offered “as is” without assurances on completeness, accuracy, or timeliness. For verification or detailed information, please consult the original articles directly.
As a leukodystrophy related nonprofit, the ULF provides awareness to scientific literature. Inclusion on our website does not imply endorsement of, or agreement with, the contents by the ULF.